US equities
|
NVDA
$125.53
▼-14.01%
ANT
$88.91
▼-8.50%
MU
$594.51
▼-13.89%
AMD
$424.39
▼-13.25%
AAPL
$342.56
▼-1.90%
MSFT
$484.52
▼-2.77%
AMZN
$246.82
▼-4.10%
AVGO
$304.41
▼-12.19%
NVDA
$125.53
▼-14.01%
ANT
$88.91
▼-8.50%
MU
$594.51
▼-13.89%
AMD
$424.39
▼-13.25%
AAPL
$342.56
▼-1.90%
MSFT
$484.52
▼-2.77%
AMZN
$246.82
▼-4.10%
AVGO
$304.41
▼-12.19%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Articles published by Ataraxis AI
Ataraxis AI to Present Nine Studies at SABCS 2026
November 20, 2026
From
Ataraxis AI
Via
Business Wire
Ataraxis AI Publishes Landmark Studies Showing Causal AI Predicts Chemotherapy Benefit in Multiple Solid Tumors
September 14, 2026
From
Ataraxis AI
Via
Business Wire
Ataraxis AI Launches ARC, a Large-Scale Prospective Study Linking AI Model Predictions to Real Patient Outcomes Across Oncology
September 08, 2026
From
Ataraxis AI
Via
Business Wire
Ataraxis AI's Laboratory Receives CAP Accreditation and California Clinical Laboratory License
August 25, 2026
From
Ataraxis AI
Via
Business Wire
Ataraxis AI Launches Ataraxis Breast NEO, a New AI Test Predicting Response to Neoadjuvant Therapy in Breast Cancer
April 09, 2026
From
Ataraxis AI
Via
Business Wire
Ataraxis AI Launches Ataraxis Breast CTX, the First Predictive AI Test Estimating Individualized Chemotherapy Benefit in Breast Cancer
March 30, 2026
From
Ataraxis AI
Via
Business Wire
Ataraxis AI and Unicancer Partner to Validate Ataraxis™ Breast Prognostic Tool Using Global Phase III Trial Data
January 05, 2026
From
Ataraxis AI
Via
Business Wire
Ataraxis AI to Present Eight Studies at SABCS 2025 Expanding Clinical Utility of Ataraxis™ Breast
November 18, 2025
From
Ataraxis AI
Via
Business Wire
MEDSIR and Ataraxis AI Launch Research Collaboration to Evaluate AI-Powered Platform as a Predictive Tool in Breast Cancer Randomized Clinical Trials
October 02, 2025
From
Ataraxis AI
Via
Business Wire
Ataraxis AI to Transform Precision Medicine in Cancer Care with $20.4 Million Series A
March 05, 2025
From
Ataraxis AI
Via
Business Wire
Ataraxis AI Launches to Transform Precision Medicine Beginning with World’s First AI-native Cancer Diagnostic
October 31, 2024
From
Ataraxis AI
Via
Business Wire